Drug Shortage Report for LABETALOL HYDROCHLORIDE INJECTION USP
| Report ID | 154106 |
| Drug Identification Number | 02231689 |
| Brand name | LABETALOL HYDROCHLORIDE INJECTION USP |
| Common or Proper name | LABETALOL HCL |
| Company Name | SANDOZ CANADA INCORPORATED |
| Market Status | MARKETED |
| Active Ingredient(s) | LABETALOL HYDROCHLORIDE |
| Strength(s) | 5MG |
| Dosage form(s) | LIQUID |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 20ML 1LIVI |
| ATC code | C07AG |
| ATC description | BETA BLOCKING AGENTS |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | 2022-02-28 |
| Actual start date | |
| Estimated end date | 2022-04-01 |
| Actual end date | 2022-03-10 |
| Shortage status | Resolved |
| Updated date | 2022-03-11 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
| Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2022-03-11 | French | Compare |
| v4 | 2022-03-10 | English | Compare |
| v3 | 2022-03-01 | English | Compare |
| v2 | 2022-02-02 | French | Compare |
| v1 | 2022-02-02 | English | Compare |
Showing 1 to 5 of 5